Radius Ready To Face Off With Amgen At ASBMR
This article was originally published in Scrip
Conducting a large osteoporosis development program is a path that Amgen Inc. has been down before, but it's a make-or-break journey for Radius Health, which had one of the most successful initial public offerings during the recent biotechnology IPO boom based on optimism about its drug abaloparatide.
You may also be interested in...
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.
The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.